Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen

Trial Profile

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Aprepitant (Primary) ; Ondansetron
  • Indications Radiotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms AVERT
  • Most Recent Events

    • 28 Dec 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 28 Dec 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.
    • 28 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top